Premium Serums AND Vaccines Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Premium Serums AND Vaccines Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $2.8M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Premium Serums AND Vaccines Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $2.8M Trade | TransData Nexus

Premium Serums AND Vaccines Private Limited

Indian Pharmaceutical Exporter · Other Specialist · $2.8M Total Trade · DGFT Verified

Premium Serums AND Vaccines Private Limited is an Indian pharmaceutical exporter with a total trade value of $2.8M across 2 products in 1 therapeutic categories. Based on 102 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Serum ($1.4M), Antitoxin ($1.4M), .

Premium Serums AND Vaccines Private Limited — Export Portfolio & Destination Treemap

Premium Serums AND Vaccines Private Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Premium Serums AND Vaccines Private Limited? — Company Overview & Market Position

Premium Serums and Vaccines Private Limited, established on January 29, 2009, is a private limited company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24110MH2009PTC189968. Its authorized and paid-up capital stands at ₹2.00 crore each. The registered office is located at 406, B Wing, Highway Rose Co-Op Hsg Society 92, Dixit Road Extension, Vile Parle (East), Mumbai, Maharashtra, 400057.

As of April 7, 2024, Premium Serums and Vaccines employed 82 professionals. The company's leadership comprises Directors Shyam Bhalchandra Dhawan and Girish Nathuram Kolwankar. In the fiscal year ending March 31, 2023, the company reported a 48.43% increase in total revenue, a 27.35% rise in profit, and a significant 386.65% growth in net worth.

What Does Premium Serums AND Vaccines Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Serum$1.4M 2Antitoxin

Product Portfolio — Top 2 by Export Value

Premium Serums AND Vaccines Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Serum	Other	$1.4M	31	5.3%	3
2	Antitoxin	Other	$1.4M	71	10.1%	2

Premium Serums AND Vaccines Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $2.8M. The top category is Other (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Premium Serums AND Vaccines Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Premium Serums and Vaccines operates manufacturing facilities in Pune, Maharashtra, and Narayangaon, Maharashtra. The Pune facility is situated at Gate No. 354-1, 354-2, At/Po, Pune, Maharashtra, 410504. The Narayangaon facility is located in the Pune district. These facilities specialize in the production of equine immunoglobulin products, including antivenoms, antitoxins, serums, and vaccines.

3Key Leadership

The company's leadership includes Directors Shyam Bhalchandra Dhawan and Girish Nathuram Kolwankar. Specific roles such as CEO, MD, and CFO are not publicly disclosed. The company employs a team of 82 professionals as of April 7, 2024.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Premium Serums AND Vaccines Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Premium Serums and Vaccines Private Limited's export data indicates a total export value of $2.8 million USD across 102 shipments, with products spanning one therapeutic category. The top two products, Serum and Antitoxin, each contributed $1.4 million USD, accounting for 5.3% and 10.1% market share, respectively. The company's portfolio is highly concentrated, with the top five products comprising 100% of exports. Specific regulatory approvals in the US, EU, UK, Australia, and Japan are not publicly disclosed.

2Emerging Markets

The company's export data does not specify its presence in African, Latin American, or Southeast Asian markets. Additionally, there is no publicly available information regarding WHO prequalification status, which is essential for accessing certain international markets.

3Geographic Strategy

Premium Serums and Vaccines Private Limited's export data indicates a highly concentrated portfolio, with the top five products comprising 100% of exports. This suggests a focused geographic strategy, potentially limiting exposure to market diversification risks. However, the lack of detailed information on geographic diversification and market penetration strategies makes it challenging to assess the company's overall geographic strategy comprehensively.

Premium Serums AND Vaccines Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history for Premium Serums and Vaccines Private Limited is not publicly available. The company's export data does not provide insights into its regulatory standing with the FDA.

2WHO & EU GMP

There is no publicly available information regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status for Premium Serums and Vaccines Private Limited. These certifications are crucial for market access in various international regions.

3CDSCO & Indian Regulatory

Specific details about the company's manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), approvals from state drug controllers, and export No Objection Certificates (NOCs) are not publicly disclosed. The company's export data does not provide insights into its regulatory standing within India.

Premium Serums AND Vaccines Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Premium Serums and Vaccines Private Limited operates in the equine immunoglobulin product segment, competing with other manufacturers in the antivenom, antitoxin, serum, and vaccine markets. Specific market share comparisons and head-to-head analyses are not publicly available. The company's export data indicates a highly concentrated product portfolio, which may impact its competitive positioning.

2Key Differentiators

The company's focus on equine immunoglobulin products, including antivenoms, antitoxins, serums, and vaccines, positions it as a specialized manufacturer in this niche segment. However, the lack of detailed information on product innovations, quality certifications, and unique selling propositions makes it challenging to identify specific competitive advantages.

3Strategic Position

Premium Serums and Vaccines Private Limited's export data indicates a highly concentrated product portfolio, with the top five products comprising 100% of exports. This suggests a focused strategic direction, potentially limiting exposure to market diversification risks. However, the lack of detailed information on the company's strategic initiatives, such as expansion into generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services, makes it challenging to assess its future outlook comprehensively.

Buyer Due Diligence Brief — Evaluating Premium Serums AND Vaccines Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

The company's export data indicates a total export value of $2.8 million USD across 102 shipments, with products spanning one therapeutic category. The top two products, Serum and Antitoxin, each contributed $1.4 million USD, accounting for 5.3% and 10.1% market share, respectively. The company's portfolio is highly concentrated, with the top five products comprising 100% of exports. Specific information regarding the company's track record, export volume consistency, and reliability indicators is not publicly available.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the company's products are approved by the U.S. Food and Drug Administration. Verification can be done through the FDA's official website or by contacting the company directly.

WHO-GMP Certification: Ensure that the manufacturing facilities comply with the World Health Organization's Good Manufacturing Practice standards. This can be verified by reviewing the company's certifications or contacting the WHO.

Frequently Asked Questions — Premium Serums AND Vaccines Private Limited

How many pharmaceutical products does Premium Serums AND Vaccines Private Limited export from India?

Premium Serums AND Vaccines Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Serum ($1.4M), Antitoxin ($1.4M). Total export value is $2.8M.

What is Premium Serums AND Vaccines Private Limited's total pharmaceutical export value?

Premium Serums AND Vaccines Private Limited's total pharmaceutical export value is $2.8M, based on 102 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Premium Serums AND Vaccines Private Limited cover?

Premium Serums AND Vaccines Private Limited exports across 1 therapeutic categories. The largest are Other (100.0%, 2 products).

Get Full Premium Serums AND Vaccines Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.